{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:42:46Z","timestamp":1788090166515,"version":"build-2803163510"},"reference-count":27,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2026.2961","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:49:21Z","timestamp":1780915761000},"page":"1-7","source":"Crossref","is-referenced-by-count":1,"title":["Occult breast cancer showing a marked response to pembrolizumab plus gemcitabine and carboplatin therapy complicated by immune\u2011related colitis: A case report"],"prefix":"10.3892","volume":"25","author":[{"given":"Wakako","family":"Inohana","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Mikami","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Nakame","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Sakakibara","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ichinose","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Nukui","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University Hospital, Moroyama\u2011machi, Saitama 350\u20110495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yokokawa","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miyama","sequence":"additional","affiliation":[{"name":"Department of Pathology, International Medical Center, Saitama Medical University, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Osaki","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350\u20111298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"key20260724093420_b1-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/EDBK_159135","article-title":"The evolution of triple-negative breast cancer: From biology to novel therapeutics","volume":"35","author":"Anders","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20260724093420_b2-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260724093420_b3-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"key20260724093420_b4-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20260724093420_b5-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28 (suppl 4)","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"key20260724093420_b6-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"394","DOI":"10.18632\/oncotarget.27877","article-title":"Tumor mutational burden as a predictor of immunotherapy response in breast cancer","volume":"12","author":"O'Meara","year":"2021","journal-title":"Oncotarget"},{"key":"key20260724093420_b7-MCO-25-2-02961"},{"key":"key20260724093420_b8-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"key20260724093420_b9-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.breast.2020.10.012","article-title":"Occult breast cancer: Where are we at?","volume":"54","author":"Ofri","year":"2020","journal-title":"Breast"},{"key":"key20260724093420_b10-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/sj.bjc.6603440","article-title":"Gemcitabine and carboplatin in carcinoma of unknown primary site: A phase 2 Adelaide cancer trials and education collaborative study","volume":"95","author":"Pittman","year":"2006","journal-title":"Br J Cancer"},{"issue":"671","key":"key20260724093420_b11-MCO-25-2-02961","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4556-6","article-title":"Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: A multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators","volume":"18","author":"Inoue","year":"2018","journal-title":"BMC Cancer"},{"key":"key20260724093420_b12-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"ESMO Guidelines Committee: Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26 (Suppl 5)","author":"Fizazi","year":"2015","journal-title":"Ann Oncol"},{"key":"key20260724093420_b13-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.6004\/jnccn.2011.0117","article-title":"NCCN clinical practice guidelines Occult primary","volume":"9","author":"Ettinger","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260724093420_b14-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/1097-0142(19870315)59:6<1170::aid-cncr2820590623>3.0.co;2-2","article-title":"Hormone receptor studies in axillary metastases from occult breast cancers","volume":"59","author":"Bhatia","year":"1987","journal-title":"Cancer"},{"key":"key20260724093420_b15-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2559.1996.tb01396.x","article-title":"Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites","volume":"29","author":"Kaufmann","year":"1996","journal-title":"Histopathology"},{"issue":"e1524695","key":"key20260724093420_b16-MCO-25-2-02961","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1524695","article-title":"Clinical characterization of colitis arising from anti-PD-1 based therapy","volume":"8","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"key20260724093420_b17-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20260724093420_b18-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","article-title":"Management of patients with immune checkpoint inhibitor\u2013induced enterocolitis: A systematic review","volume":"18","author":"Collins","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20260724093420_b19-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"633032","key":"key20260724093420_b20-MCO-25-2-02961","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: A systemic review and meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"key20260724093420_b21-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1111\/1759-7714.15433","article-title":"A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report","volume":"15","author":"Koi","year":"2024","journal-title":"Thorac Cancer"},{"issue":"e124507","key":"key20260724093420_b22-MCO-25-2-02961","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"issue":"24","key":"key20260724093420_b23-MCO-25-2-02961","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0514-3","article-title":"Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer","volume":"7","author":"Mishima","year":"2019","journal-title":"J Immunother Cancer"},{"key":"key20260724093420_b24-MCO-25-2-02961","doi-asserted-by":"publisher","DOI":"10.1159\/000549852","article-title":"Lymphatic metastasis predicts better response to nivolumab in recurrent or metastatic gastric cancer: Insights from tumor-draining lymph node immunity and long-term outcomes","volume":"1-9","author":"Oya","year":"2025","journal-title":"Oncology"},{"key":"key20260724093420_b25-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20260724093420_b26-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"key20260724093420_b27-MCO-25-2-02961","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: Management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:34:26Z","timestamp":1784874866000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2026.2961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,8]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2026.2961","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}